Lynch Thomas P. sold $3.9M of BLLN

Lynch Thomas P. (See Remarks) sold 35,112 shares of BillionToOne, Inc. (BLLN) at an average of $110.33 ($110.29–$110.36, $3.87M total) across 4 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lynch Thomas P.
Published Sep 21, 2026, 11:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Bearish
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNBearishLow
01

Why it matters

The insider reduction to 700 shares may be interpreted as a bearish signal, but the pre‑arranged nature tempers urgency.

02

Market read

Primary disclosure of a sizable insider sell; modest trading relevance for short‑term positioning.

03

What to watch

Potential tax or liquidity reasons for the sale; no immediate change in company fundamentals.

Relevance 5/10Novelty 5/10Timing: filed 2026-09-21

Background

Form 4 filings disclose insider transactions; a $3.9M sale by an officer is a primary source of new information.

Company-level read

Ticker impact

$BLLNBearishMedium confidence
Context

Officer Lynch Thomas P. sold 35,112 shares for $3.9M via a 10b5-1 plan, reducing his stake to 700 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

Large insider sale relative to holdings suggests lack of confidence; however, the sale is pre‑arranged, limiting immediate predictive power.

Market effects

Minimal; the sale is company‑specific and does not affect the broader sector.

Negligible impact on regional markets.

None.

Counterpoint

The 10b5‑1 plan may have been set earlier; the sale does not necessarily reflect current outlook.

Key entities

  • BillionToOne, Inc.

    Issuer of the stock BLLN.

  • Lynch Thomas P.

    Officer and reporting insider.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.